Related Experiment Video
Updated: May 4, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
18.2K
[Frontotemporal dementia: clinical features, genetics, pathogenesis and treatment]
Hanna Rosenmann1, Zeev Meiner2
1The Agnes Ginges Center for Human Neurogenetics, Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem.
Harefuah
|January 15, 2014
Summary
Frontotemporal dementia (FTD) is a common cause of early-onset dementia. Understanding its diverse pathology and genetic links is key to developing effective treatments for this progressive neurodegenerative disorder.
Area of Science:
- Neuroscience
- Genetics
- Pathology
Context:
- Frontotemporal dementia (FTD) is the second leading cause of dementia in younger individuals, following Alzheimer's disease.
- FTD is characterized by progressive behavioral, personality, and language impairments.
- It is a complex disorder with significant clinical, pathological, and genetic variability.
Purpose:
- To review the clinical, pathological, and genetic heterogeneity of Frontotemporal Dementia (FTD).
- To discuss the correlation between clinical presentations and pathological findings in FTD.
- To highlight recent advancements in FTD classification and therapeutic research.
Summary:
- FTD exhibits diverse histopathological features, including tau, TDP-43, and FUS protein inclusions.
- Genetic factors, such as mutations in MAPT, GRN, and C9ORF72, contribute to familial FTD.
- A new classification system categorizes FTD based on protein aggregates (FTLD-Tau, FTLD-TDP43, FTLD-FUS).
Impact:
- Understanding the link between FTD subtypes and clinical symptoms aids in elucidating disease mechanisms.
- Advances in pathological classification and genetic understanding are crucial for developing targeted therapies.
- Despite the lack of current effective treatments, ongoing research offers hope for future therapeutic breakthroughs.
More Related Videos
08:33Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models
Published on: March 24, 2019
6.9K
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
13.9K
Related Concept Videos
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:24Parkinson Disease ll: Pathophysiology
28
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:30Dementia
687
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
687